IQVIA Holdings Inc

IQVIA Holdings Inc

IQV

Get informed when a big investor buys or sells

+ Follow
Market Cap$38.68B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
IQVIA Holdings IncIQVIA Holdings Inc28.9-22%2.33

Earnings Call Q2 2026

July 28, 2026 - AI Summary

Q2 performance beat (strong execution + improving organic growth): - IQVIA reported Q2 revenue $4.368B (+8.7% YoY reported; +8.5% constant currency)—above the high end of guidance. - Adjusted EBITDA $994M (+9.2% YoY)—also above the high end of guidance; management noted EBITDA margin began improving earlier than expected. - Adjusted diluted EPS $3.15 (+12.1% YoY)—above the high end; the EPS beat was attributed entirely to operational performance. - Organic growth accelerated to 6% YoY (called out as ~3x faster than a year ago).
Segment momentum + demand signals (bookings strength is a key “surprise” positive): - R&D Solutions: ~9% revenue growth, ~7% organic; net new bookings $3.15B (+19% YoY; +27% sequential); book-to-bill 1.22 (noted as especially strong because revenue was already up). - Long-cycle validation: “Last 12-month” net new bookings $11.3B (+13% YoY) and up in each of the past 4 quarters—management views this as evidence of a consistently improving demand/win-rate environment. - Commercial Solutions: ~5% organic (up from >4 points higher than last year); analytics & consulting high-single digits (highest since 2022); engagement + patient solutions double-digit growth; AI offerings gaining traction. - Market/demand indicators: strong RFP flow growth (double-digit YoY and sequential), shorter decision timelines, and EBP funding $35B (BioWorld) in Q2 2026—more than double Q2 2025.
Updated customer segment definitions + strategic implications (opportunity clearer): - To better benchmark peers, IQVIA updated classification: Large pharma = top 20 by Rx sales; Midsize = next 60; EBPs = everyone else. - Mix in R&D revenue: Large pharma ~50%, Midsize ~15%, EBPs ~35%—management emphasized EBPs are where much innovation is concentrated. - Structural tailwind: EBPs now ~70% of global clinical trial starts (vs ~45% a decade ago); EBP spend expected to grow 2–3x large pharma. - Management claims improving win rates with large pharma (via expanded preferred partnerships) is helping replace incumbents and increase share of wallet.

Exclusive for Stockcircle Pro members

Sign upSign Up
$234.82

Target Price by Analysts

0.1% downsideIQVIA Holdings Target Price DetailsTarget Price
$208.40

Current Fair Value

11.3% downside

Overvalued by 11.3% based on the discounted cash flow analysis.

Share Statistics

Market cap$38.68 Billion
Enterprise Value$55.47 Billion
Dividend Yield$- (-)
Earnings per Share$7.91
Beta1.2
Outstanding Shares167,200,000

Return

Return on Equity22.28%ROE
Return on Assets4.60%
Return on Invested Capital11.10%

Valuation & Multiples

P/E Ratio28.91P/E Ratio
PEG-768.95PEG
Price to Sales2.33Price to Sales
Price to Book Ratio6.35Price to Book Ratio
Enterprise Value to Revenue3.27
Enterprise Value to EBIT23.72
Enterprise Value to Net Income40
Total Debt to Enterprise0.34
Debt to Equity3.03Debt to Equity

Revenue Sources

No data

Insider Trades

Last Earnings Call

Report Date
July 28, 2026
EPS Estimate
$3.03
Average shareholder expectation
Revenue Estimate
$4.30 B
Average shareholder expectation

Next Earnings Call

Expected Date
October 27, 2026
EPS Estimate
$3.27
Average shareholder expectation
Revenue Estimate
$4.36 B
Average shareholder expectation

Institutional Put/Call Ratio

Market sentiment based on institutional option activity.

Put/Call Ratio0.0000▼ 99.10%
Total Calls-▼ 100.00%
Total Puts1,000▼ 99.88%

Institutional Ownership

Holdings and activity of institutional investors.

Ownership %4.54%▼ 87.64%
Total Invested$1.47B▼ 94.52%
Investors Holding403▼ 694.00%

ESG Score

No data

About IQVIA Holdings Inc

CEO: Ari Bousbib

Relevant Senate Committees

Joint Committee on Taxation

This committee provides the technical analysis and revenue estimates for all tax legislation, directly influencing corporate tax policy that impacts IQVIA's profitability, capital investment, and overall financial health.

Finance

This committee's control over taxation, trade, and entitlement spending (like Medicare) directly impacts corporate profitability, healthcare sector funding, and drug pricing, all of which critically affect IQVIA's clients and, by extension, its business model.

Appropriations

This committee directly allocates federal spending, and its subcommittees can determine funding for health programs, scientific research, and healthcare-related initiatives that IQVIA or its clients may participate in or benefit from.

Health, Education, Labor, and Pensions

This committee directly regulates the FDA and NIH, which are central to the drug approval process and research funding, both core to IQVIA's clinical research and life sciences services. Labor laws also impact its workforce.